Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
Status:
Not yet recruiting
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP
regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.